Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 39

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 39
---
* Represents beneficial ownership of less than 1%. (1) The shares listed are based on the shares reported on a Schedule 13D/A filed with the SEC on March 12, 2025, with respect to shares of Common Stock held by Innoviva, Inc. and Innoviva Strategic

26

Opportunities, LLC and other information available to the Company. Includes (i) 8,710,800 shares of Common Stock held by Innoviva, Inc.; (ii) 16,365,969 shares of Common Stock held by Innoviva Strategic Opportunities, LLC; (iii) 10,653,847 shares of Common Stock issuable upon exercise of the warrants to purchase Common Stock held by Innoviva Strategic Opportunities, LLC; and (iv) 23,368,422 shares of Common Stock issuable to Innoviva Strategic Opportunities, LLC upon the conversion of a certain convertible loan (including accrued interest as of April 17, 2025). The principal business address of the reporting persons is c/o Innoviva, Inc., 1350 Old Bayshore Highway, Suite 400, Burlingame, CA 94010. Innoviva designated Jules Haimovitz and Odysseas Kostas, M.D., two of the members of the board of directors of Innoviva, to serve on our Board. Additionally, Sarah Schlesinger, M.D., is a member of the board of directors of Innoviva. As such, solely for purposes of Section 16 of the Exchange Act of 1934, as amended, Innoviva, Inc. and Innoviva Strategic Opportunities, LLC may be deemed to be directors by deputization. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the Board approved the acquisition of any direct or indirect pecuniary interest in any shares of common stock, including any shares of common stock issuable upon the exercise of the aforementioned warrants. (2) Consists of (i) 36,014 shares of Common Stock issued upon Restricted Stock Units vested during 2024 and 2025 and (ii) 110,000 shares of Common Stock that Dr. Birx has the right to acquire from us within 60 days of April 17, 2025 pursuant to the exercise of stock options. Does not include 195,000 shares of unvested Restricted Stock Units that do not vest within 60 days of April 17, 2025 or entitle Dr. Birx to